Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Malaysian Genomics Resource Centre BhdXKLS:0155 46 3-Year EBITDA Growth Rate is 41.00% as of Mar. 2026, which is 99% above its 10-year median of 20.60. GuruFocus rates XKLS:0155 with a GF Score™ of 46/100 and a GF Value™ of RM0.31 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Malaysian Genomics Resource Centre Bhd ranks better than 79.64% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 41.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Malaysian Genomics Resource Centre Bhd was 41.00% per year. The lowest was -17.40% per year. And the median was 20.60% per year.
Malaysian Genomics Resource Centre Bhd (XKLS:0155) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Malaysian Genomics Resource Centre Bhd 3-Year EBITDA Growth Rate Related Terms
XKLS:0155 vs TMO, DHR, NTRA: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Malaysian Genomics Resource Centre Bhd's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Malaysian Genomics Resource Centre Bhd 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Malaysian Genomics Resource Centre Bhd's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Malaysian Genomics Resource Centre Bhd's 3-Year EBITDA Growth Rate falls into.
Malaysian Genomics Resource Centre Bhd 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 41.00% mean?
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a 3-Year EBITDA Growth Rate of 41.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Malaysian Genomics Resource Centre Bhd and its competitors. This is 99% above median its historical median of 20.60. According to the industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #34 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 20.4%.
Is Malaysian Genomics Resource Centre Bhd's 3-Year EBITDA Growth Rate too high?
Malaysian Genomics Resource Centre Bhd's current 3-Year EBITDA Growth Rate of 41.00% is 99% above median its 10-year median of 20.60. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.00. Malaysian Genomics Resource Centre Bhd's value of 41.00% is 272.7% above this industry median. Based on the distribution chart, Malaysian Genomics Resource Centre Bhd ranks #34 out of 167 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #34 out of 167 companies for 3-Year EBITDA Growth Rate. This places Malaysian Genomics Resource Centre Bhd in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 11.00. Malaysian Genomics Resource Centre Bhd's value of 41.00% is 272.7% above this benchmark. While the company's 10-year median is 20.60 vs. the industry median of 11.00, Malaysian Genomics Resource Centre Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Malaysian Genomics Resource Centre Bhd's current 3-Year EBITDA Growth Rate of 41.00% is 272.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Malaysian Genomics Resource Centre Bhd and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Malaysian Genomics Resource Centre Bhd's current 3-Year EBITDA Growth Rate is 41.00%, which is 99% above median its own 10-year median of 20.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Modestly Overvalued. The stock's GF Value™ is RM0.31, compared to a current price of RM0.37 — trading 19.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 41.00%, which is 99% above median its 10-year median of 20.60 and 272.7% above the Medical Diagnostics & Research industry median of 11.00. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current 3-Year EBITDA Growth Rate is 41.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be overvalued.
The current stock price of RM0.37 is trading 19.4% above its estimated GF Value™ of RM0.31.
GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Modestly Overvalued.
Key valuation signals for XKLS:0155:
3-Year EBITDA Growth Rate: 41.00% (99% above median its 10-year median of 20.60)
GF Value™: RM0.31 vs. price of RM0.37 (19.4% above fair value)
Industry Position: 272.7% above the Medical Diagnostics & Research median (#34 of 167)
No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
46GF Score
Get the complete analysis for XKLS:0155
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0155 has been successfully added to your 
